296 completed, 22 terminated, 10 unknown, 8 withdrawn. 339 Phase 1, 57 Phase 2.
Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) AVIHepC1, Normal Saline - Hepatitis C | Phase 1 | Not yet recruiting | University of Alberta | 27 | 2027-01-15 | 2026-09-25 |
| Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV Glecaprevir/pibrentasvir - Hepatitis C | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2026-06-25 | 2026-08-14 |
| The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART) Anakinra - Heart Failure | Phase 1 | Completed | Virginia Commonwealth University | 4 | 2024-02-05 | 2026-09-04 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-05-28 | 2022-05-24 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
| Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir Sofosbuvir-Velpatasvir Drug Combination - Hepatitis C, Chronic | Phase 1 | Completed | Catherine Anne Chappell | 11 | 2020-10-22 | 2025-01-01 |
| Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects HEC74647, HEC110114 - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 28 | 2020-07-15 | 2020-11-05 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C | Phase 1 / Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 24 | 2020-07-06 | 2020-09-10 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects HEC74647PA capsule, placebo - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 28 | 2019-12-18 | 2020-03-19 |
| Expanding the Pool in Lung Transplantation Epclusa - Hepatitis C, Lung Transplant | Phase 1 | Completed | Pablo Sanchez | 10 | 2019-07-30 | 2022-12-16 |
| Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet Zepatier whole tablet, Zepatier crushed tablet - Hepatitis C, Deglutition Disorders | Phase 1 | Completed | Radboud University Medical Center | 11 | 2019-03-28 | 2020-10-19 |
| The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects HEC110114 tablet, Placebo Oral Tablet - Chronic Hepatitis C | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 93 | 2019-03-06 | 2020-03-18 |
| Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Ain Shams University | 24 | 2019-03-01 | 2023-08-22 |
| Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection GLS-6150 - HCV Infection | Phase 1 | Completed | GeneOne Life Science, Inc. | 32 | 2018-09-04 | 2020-05-27 |
| The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects HEC74647PA Capsule, placebo - Chronic Hepatitis c | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 105 | 2018-09-04 | 2020-03-19 |
| Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole. velpatasvir - Hepatitis C, Swallowing Disorder | Phase 1 | Completed | Radboud University Medical Center | 11 | 2018-08-01 | 2020-10-19 |
| Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis PRI-724 - Hepatitis C, Hepatitis B | Phase 1 / Phase 2 | Completed | Kiminori Kimura, MD | 27 | 2018-07-24 | 2024-10-10 |
| Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection SH229, Placebos - HCV Infection | Phase 1 | Completed | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 30 | 2018-07-07 | 2018-08-28 |
Showing 20 of 339. Sign in to see all of them.
Hepatitis C, Chronic (105) · HIV Infections (13) · Hepatitis (10) · Liver Diseases (10) · Virus Diseases (8) · Hepatitis, Chronic (7) · Acquired Immunodeficiency Syndrome (5) · Bronchiolitis Obliterans Syndrome (5) · Hepatitis B (5) · Adenoviridae Infections (4) · Fibrosis (4) · Infections (4) · Liver Cirrhosis (4) · Carcinoma, Hepatocellular (3)
Blood-Borne Infections (339) · Communicable Diseases (337) · Digestive System Diseases (337) · RNA Virus Infections (337) · Flaviviridae Infections (336) · Hepatitis, Viral, Human (336) · Infections (335) · Virus Diseases (331) · Hepatitis (329) · Liver Diseases (329) · Pathologic Processes (123) · Pathological Conditions, Signs and Symptoms (123) · Disease Attributes (115) · Chronic Disease (112) · Hepatitis, Chronic (105)
Ribavirin (28) · Simeprevir (26) · Ritonavir (19) · telaprevir (17) · 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide (11) · daclatasvir (10) · asunaprevir (8) · peginterferon alfa-2a (8) · peginterferon alfa-2b (7) · faldaprevir (6) · samatasvir (6) · ABT-072 (5) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (5) · filibuvir (5) · grazoprevir (5)
Merck Sharp & Dohme LLC (41) · Bristol-Myers Squibb (26) · Tibotec Pharmaceuticals, Ireland (25) · Gilead Sciences (13) · Abbott (11) · Boehringer Ingelheim (11) · National Institute of Allergy and Infectious Diseases (NIAID) (10) · Vertex Pharmaceuticals Incorporated (10) · GlaxoSmithKline (9) · Hoffmann-La Roche (8) · Pfizer (8) · Sunshine Lake Pharma Co., Ltd. (7) · Tibotec BVBA (7) · Alios Biopharma Inc. (5) · Janssen R&D Ireland (4)
United States (134) · Puerto Rico (23) · Germany (18) · New Zealand (16) · Belgium (15) · France (15) · United Kingdom (15) · Canada (11) · Netherlands (11) · China (10) · Japan (7) · Australia (6) · Switzerland (5) · Israel (4) · Italy (4)
Yanhua Ding, Doctor (5) · Daniel Cohen, MD (4) · Nathaniel Brown, M.D. (3)
PMID 21488067, PMID 33317695, PMID 1538192, PMID 15577929, PMID 16375711, PMID 19852962, PMID 20619382, PMID 20938912, PMID 20951424, PMID 21060109, PMID 21145839, PMID 21354234, PMID 21699798, PMID 21751289, PMID 21865319, PMID 22239508, PMID 22414766, PMID 22425702, PMID 23070151, PMID 23183437, PMID 23190247, PMID 23396509, PMID 23490393, PMID 23717490, PMID 23747481, PMID 23856771, PMID 23872824, PMID 23877691, PMID 23877706, PMID 23982366, PMID 24041792, PMID 24097843, PMID 24145880, PMID 24295986, PMID 24434503, PMID 24610312, PMID 24733462, PMID 24876849, PMID 24982088, PMID 24983321, PMID 25101888, PMID 25105516, PMID 25155588, PMID 25378645, PMID 25385094, PMID 25385099, PMID 25426834, PMID 25451055, PMID 25456558, PMID 25622055
2009 (7), 2015 (4), 2008 (3), 2014 (2), 2016 (1), 2019 (1), N01CN00042 (1), P30CA015083 (1), R01AI049141 (1), R01AI065256 (1), R01DK090794 (1), R21AI066957 (1), R21AT003892 (1), R21HD101996 (1), R21NR008860 (1)